药石科技(300725) - 2023 Q3 - 季度财报

Financial Performance - Q3 2023 revenue was CNY 447,403,599.41, a decrease of 0.59% year-over-year, while year-to-date revenue increased by 9.01% to CNY 1,291,461,856.48[6] - Net profit attributable to shareholders for Q3 2023 was CNY 40,155,270.39, down 58.40% year-over-year, and year-to-date net profit decreased by 38.29% to CNY 154,046,269.72[6] - Basic earnings per share for Q3 2023 was CNY 0.2011, a decline of 58.60% compared to the same period last year, with year-to-date earnings per share at CNY 0.7715, down 38.62%[6] - The company reported a net loss of approximately CNY 40.4873 million from foreign exchange hedging activities due to significant fluctuations in the RMB to USD exchange rate[18] - The total comprehensive income for Q3 2023 was CNY 156,901,390.33, a decrease of 40.0% from CNY 261,617,396.78 in Q3 2022[27] Assets and Liabilities - Total assets as of September 30, 2023, were CNY 5,216,645,916.42, reflecting a 7.29% increase from the end of the previous year[6] - The total liabilities of the company as of September 30, 2023, were CNY 2,407,674,279.23, compared to CNY 2,204,553,130.65 at the beginning of the year, reflecting an increase of approximately 9.21%[23] - The company's equity attributable to shareholders increased to CNY 2,808,971,645.80 from CNY 2,657,635,982.95, representing a growth of about 5.68%[23] Cash Flow and Investments - Cash flow from operating activities for the year-to-date period was CNY 148,570,068.07, down 20.31%[6] - The company experienced a decrease in cash received from investment recoveries, totaling CNY 1.524 billion, down 39.87% due to reduced redemption of maturing financial products[11] - Investment cash payments were CNY 1.704 billion, a decrease of 48.61% compared to the previous year, primarily due to reduced purchases of financial products[11] - The company reported a basic earnings per share of CNY 0.7715, down from CNY 1.2570 in the same quarter last year[27] - The company received CNY 20.91 million in investment income, an increase of 89.53% due to higher financial product returns[11] Sales and Expenses - The company reported a significant increase in sales expenses by 32.88% to CNY 41,155,552.09, reflecting efforts to expand the sales team and drive business growth[10] - Operating costs for the current period were CNY 1,089,728,764.88, up from CNY 892,450,688.06 in the previous period, reflecting an increase of approximately 22.08%[25] - Research and development expenses for the current period were CNY 132,533,134.98, compared to CNY 121,203,263.82 in the previous period, indicating an increase of approximately 9.86%[25] Revenue Breakdown - Revenue from the novel molecular building blocks product line, focused on drug chemistry, was CNY 269 million for the first three quarters, which was flat compared to the previous year[18] - The CDMO revenue for the first three quarters was CNY 997 million, an increase of 9.62% year-on-year[18] - The company's total revenue for the current period reached CNY 1,291,461,856.48, compared to CNY 1,184,702,109.49 in the previous period, indicating a year-over-year increase of about 9.05%[25] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 29,319, with the largest shareholder holding 20.69% of the shares[13] - The company has approved a share repurchase plan proposed by its controlling shareholder, Mr. Yang Minmin, on October 25, 2023[19]